GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (HAM:MYD) » Definitions » Days Sales Outstanding

Myriad Genetics (HAM:MYD) Days Sales Outstanding : 52.87 (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Days Sales Outstanding?

Myriad Genetics's average Accounts Receivable for the three months ended in Sep. 2024 was €111.3 Mil. Myriad Genetics's Revenue for the three months ended in Sep. 2024 was €192.2 Mil. Hence, Myriad Genetics's Days Sales Outstanding for the three months ended in Sep. 2024 was 52.87.

The historical rank and industry rank for Myriad Genetics's Days Sales Outstanding or its related term are showing as below:

HAM:MYD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.33   Med: 46.06   Max: 57.73
Current: 52.39

During the past 13 years, Myriad Genetics's highest Days Sales Outstanding was 57.73. The lowest was 41.33. And the median was 46.06.

HAM:MYD's Days Sales Outstanding is ranked better than
65.89% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: 65.49 vs HAM:MYD: 52.39

Myriad Genetics's Days Sales Outstanding declined from Sep. 2023 (53.55) to Sep. 2024 (52.87).

Myriad Genetics Days Sales Outstanding Historical Data

The historical data trend for Myriad Genetics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Days Sales Outstanding Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.35 57.60 42.18 50.36 53.04

Myriad Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.55 53.84 52.36 50.64 52.87

Competitive Comparison of Myriad Genetics's Days Sales Outstanding

For the Diagnostics & Research subindustry, Myriad Genetics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myriad Genetics's Days Sales Outstanding Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Days Sales Outstanding falls into.


Myriad Genetics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Myriad Genetics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (95.91 + 104.813) / 2 ) / 690.684*365
=100.3615 / 690.684*365
=53.04

Myriad Genetics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

Days Sales Outstanding (Q: Sep. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2024 ) + Accounts Receivable (A: Sep. 2024 )) / count ) / Revenue (A: Sep. 2024 )*Days in Period
=( (109.436 + 113.256) / 2 ) / 192.183*365 / 4
=111.346 / 192.183*365 / 4
=52.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics  (HAM:MYD) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Myriad Genetics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (HAM:MYD) » Definitions » Days Sales Outstanding
Comparable Companies
CDNA OPK CSTL NEO GRAL FLGT TWST ACRS ATLN PSNL TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA
Traded in Other Exchanges
MYGN:USA 0K3W:UK MYD:Germany MYD:Germany
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Website
https://www.myriad.com
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.